Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.

  title={Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.},
  author={Anil Gupta and Yaneicy Gonzalez-Rojas and Erick Juarez and Manuel Crespo Casal and Jaynier Moya and Diego Rodrigues Falci and Elias H. Sarkis and Joel Solis and Hanzhe Zheng and Nicola E Scott and Andrea L. Cathcart and Christy M. Hebner and Jennifer E. Sager and Erik Mogalian and Craig Tipple and Amanda F. Peppercorn and Elizabeth Alexander and Phillip S. Pang and Almena L. Free and Cynthia Brinson and Melissa Aldinger and Adrienne E. Shapiro},
  journal={The New England journal of medicine},
BACKGROUND Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the… 
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
Efficacy and safety of bamlanivimab may differ depending on whether an endogenous nAb response has been mounted, and the limited sample size of the study does not allow firm conclusions based on these findings.
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
High titer convalescent plasma is an effective early outpatient COVID-19 treatment with the advantages of low cost, wide availability, and rapid resilience to variant emergence from viral genetic drift in the face of a changing pandemic.
Antibody therapy reverses biological signatures of COVID-19 progression
Understanding who is at risk of progression to severe COVID-19 is key to effective treatment. We studied correlates of disease severity in the COMET-ICE clinical trial that randomized 1:1 to placebo
Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients
Real-world evidence demonstrated mAb effectiveness in reducing hospitalization among COVID-19 outpatients, including during the Delta variant phase, and conferred an overall 89% reduction in 28-day mortality.
Interim-analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry
The treatment of COVID-19 patients with Seraph®100 is well tolerated and the circuit failure rate was lower than previously reported for KRT in COVID patients, and mortality of Seraph®,100 treated patients reported in the registry was lower.
The persistence of viable SARS-CoV-2 in patients treated with sotrovimab and the rapid development of spike gene mutations that have been shown to confer high level resistance to sotovimab in vitro are reported.
Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
The potential therapeutic and prophylactic interventions including repurposed drugs and the newly developed/approved vaccines are discussed, highlighting the impact of virus evolution on the immune evasion of the virus from currently licensed vaccines for COVID-19.